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Abstract
Background
Short sleep and poor sleep quality are associated with risk of cardiovascular disease, diabe-
tes, cancer, and mortality. This study examines the contribution of sleep duration and sleep
quality on a multisystem biological risk index that is known to be associated with morbidity
and mortality.
Methods
Analyses include a population-based sample from the Midlife Development in the United
States survey recruited to the Biomarker substudy. A total of 1,023 participants aged 54.5
years (SD = 11.8), 56% female and 77.6% white, were included in the analyses. A multisys-
tem biological risk index was derived from 22 biomarkers capturing cardiovascular, im-
mune, lipid-metabolic, glucose-metabolic, sympathetic, parasympathetic, and
hypothalamic-pituitary-adrenal systems. Self-reported average sleep duration was catego-
rized as short (<5 hrs), below normal (5 to<6.5 hrs), normal (6.5 to<8.5 hrs), and long
sleepers (8.5+ hrs). Sleep quality was determined using the Pittsburgh Sleep Quality Index
categorized as normal (5) and poor quality (>5) sleep.
Findings
Linear mixed effect models adjusting for age, gender, race, education, income, BMI, and
health status were performed. As compared to normal sleepers, multisystem biological risk
in both short (B(SE) = .38(.15), p<.01) and long sleepers (B(SE) = .28(.11), p<.01) were el-
evated. Poor quality sleep alone was associated with elevated multisystem biological risk
(B(SE) = .15(.06), p = .01), but was not significant after adjustment for health status. All
short sleepers reported poor sleep quality. However in the long sleepers, only those who re-
ported poor sleep quality exhibited elevated multisystem biological risk (B(SE) = .93(.3), p =
.002).
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Conclusions
Self-reported poor sleep quality with either short or long sleep duration is associated with
dysregulation in physiological set points across regulatory systems, leading to elevated
multisystem biological risk. Physicians should inquire about sleep health in the assessment
of lifestyle factors related to disease risk, with evidence that healthy sleep is associated with
lower multisystem biological risk.
Introduction
Insufficient sleep is a major public health epidemic [1,2], with estimates that between 9 and
13% of adults in the United States are not getting enough sleep [3,4]. The prevalence of inade-
quate sleep in employed adults is higher, with approximately 30% reporting short sleep dura-
tion (CDC) [1]. This is a particular concern given the growing evidence that short sleep
duration increases risk for disease and death [5–7]. By contrast, excessive sleeping has also
been related to increased risk, with speculation that long sleep may be related to risk primarily
because it serves as a proxy indicator that an individual has sleep fragmentation and/or failing
health [5,6,8]. In a recent meta-analysis, both short and long sleep duration are significant pre-
dictors of all-cause mortality, including cardiovascular and non-cardiovascular deaths.5 How-
ever, a majority of these findings [sleep duration-mortality relationship] do not consider other
dimension of sleep that contribute to sleep quality. Poor sleep quality (e.g. difficulty falling
asleep, staying asleep, early awakening) has itself been related to risk. However, this relation-
ship is particularly pronounced when occurring with short sleep duration, in which the combi-
nation of poor sleep quality and short sleep duration predicts higher risk for hypertension, type
2 diabetes, and mortality than either poor sleep quality or short sleep duration alone [9–12].
Likewise, poor sleep quality among long sleepers is predictive of cardiovascular disease [12,13].
Additional research is needed to characterize the role of sleep quality in both short and long
sleepers in relation to biomarkers of disease risk.
The mechanisms through which short and long sleep duration, particularly when combined
with poor sleep quality, contribute to elevated risk are not clear, but are likely multidimension-
al. In the case of short sleep duration and poor quality sleep, a prevailing supposition is that in-
sufficient sleep, either of reduced absolute length or of poor quality, acts as a physiological
stressor, impacting neurobiological regulation of circadian rhythm [14]. This physiological
stress leads to a greater burden on the regulatory systems to maintain allostasis under adverse
conditions, which causes wear and tear across systems, termed allostatic load [14–16]. Allo-
static load is witnessed by shifts in regulatory set points that imply cumulative burden on those
systems. Some examples of shifts in set points include elevated resting blood pressure, in-
creased glucose, increased autonomic imbalances, alterations in diurnal patterns of cortisol,
and inflammation [15,17,18]. Under experimentally induced short sleep duration, either acute
sleep deprivation or sleep restriction for several days, are reported to cause temporary changes
in biomarkers for the metabolic, endocrine, autonomic, cardiovascular, and immune systems
[19–31]. Similarly, sleep fragmentation, a major component of poor sleep quality, has also been
shown to impact many of these systems [32–35]. Chronic short sleep duration, particularly
when combined with poor sleep quality [36], may have cumulative effects with a large body of
research documenting associations of short sleep with higher rates of metabolic syndrome [7],
obesity [37], diabetes [38,39], dyslipidemia, increased proinflammatory profiles [40,41], and el-
evated blood pressure [42–44]. Chronic poor sleep quality has also been linked to many of
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these health outcomes, including diabetes [45,46], inflammation [47,48], metabolic syndrome
[49], and cardiovascular disease and death [12,13,50]. Short sleep duration is thought to put
physical stress on neuroendocrine and automatic regulatory systems [14], with evidence of
short sleep being related to shifts in diurnal cortisol rhythms and altered sympathovagal bal-
ance, with elevated sympathetic and reduced parasympathetic control [38,51–53]. Sleep frag-
mentation is also thought to modify these neuroendocrine and autonomic regulatory systems
[32–35]. Moreover, Vgontzas and colleagues work argues that short sleep when combined with
poor sleep quality (i.e., insomnia complaints) is particularly detrimental to these systems and
elevates disease risk [54–57]. Taken together this work suggests that not getting adequate and
good quality sleep impacts regulatory dynamics across neuroendocrine, sympathovagal, car-
diovascular, metabolic, and immune systems, and might contribute to multisystem
biological risk.
The majority of research to date has focused on each system separately, despite evidence
that these multiple physiological systems interact with each other [11] and alter the cumulative
whole. A multisystem approach is grounded in evidence that the multiple routes are likely to
contribute to disease, which together acts as a powerful epidemiological predictor of morbidity
and mortality outcomes [16,17,58–61]. To date, two studies have evaluated sleep in relations to
multisystem risk using eight to nine biomarker to capture allostatic load, and report that short
sleep [62,63], particularly with poor sleep quality [63], and insomnia symptoms [62] related to
elevated allostatic load. These studies included biomarkers of the cardiovascular, metabolic,
and immune systems, but did not assess sympathovagal or neuroendocrine parameters. The
present analysis are the first to consider the cumulative effects across seven biological regulato-
ry systems, and similar to these previous reports, we approach the analyses using a
multisystem perspective.
Consistent with existing evidence linking short sleep duration with elevated risk within indi-
vidual systems, we hypothesized that individuals with short sleep duration would have greater
multisystem biological risk scores, indicative of higher allostatic load independent of chronic
health conditions. In addition, we examine the association between long sleep and multisystem
biological risk. Whereas long sleep is associated with increased health risks, it has been sug-
gested that this relationship reflects underlying problems in health and/or sleep quality that in-
creases demands for sleep for a longer period of time, as opposed to long sleep alone leading to
health declines [5,6,8]. Hence, we further hypothesize that the associations between long sleep
and elevated multisystem biological risk scores would be present in the long sleepers with poor
sleep quality but not with normal sleep quality. In addition, since sleep quality and depression
have both independent and overlapping effects on risk [64], we examine the effects after further
adjustment for depression. We test these hypotheses in a large community sample of midlife
adults from the United States of America.
Methods
Participants
As was previously reported [65–68], the Midlife Development in the United States (MIDUS)
survey was conducted in 1995 to 1996 and consisted of a random-digit telephone dialing of po-
tential respondents aged 25–74 years across the 48 contiguous states, including an over-sam-
pling of twin pairs and siblings. In 2004 to 2006, a follow up was completed (MIDUS II), with
75% of MIDUS I participating. The present set of analyses includes a subset of MIDUS II par-
ticipants who agreed to be in the Biomarkers substudy [68]. A total of 1255 participants came
for an overnight stay at a general clinical research center (GCRC) housed at the University of
California, Los Angeles, Georgetown University, and the University of Wisconsin, Madison.
Sleep and Disease Risk
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Institutional review board monitoring and approval was obtained from the University of Cali-
fornia Los Angeles Institutional Review Board, Georgetown University Institutional Review
Board, and the University of Wisconsin Health Sciences Institutional Review Board. All partici-
pants provided written informed consent. A detailed comparison of participants in the Bio-
marker substudy with the main sample respondents can be found elsewhere [68]. The present
analyses include 1,023 participants who took part in the Biomarker substudy, reported no regu-
lar use of medication for sleep, provided biomarkers to compute multisystem biological risk
and completed questionnaire on sleep, depression, self-evaluated health, and other psychoso-
cial, behavioral, and health questionnaires.
Procedures
Demographic information was obtained during an initial telephone interview. After arrival at
the GCRC, participants completed a medical history, health and behavior questionnaires, and
underwent a physical examination. Fasting morning blood was collected after a night of sleep
for the measurement of blood derived biomarkers. A 12-hour overnight protocol for the collec-
tion of urine was followed from 7:00 PM to 7:00 AM. Resting heart-rate variability was ob-
tained the morning following breakfast. All collection was done following standardized
protocols across sites [68].
Measures
Sleep duration. Average night time sleep duration over the prior month was reported by sub-
jects using a standard question from the Pittsburgh Sleep Quality Index (PSQI) [69]. Consis-
tent with the epidemiological literature examining sleep duration with morbidity and mortality
[5,6], we categorized sleep duration into four groups: Less than 5 hours, 5 to less than 6.5
hours, 6.5 to less than 8.5 hours, and 8.5 hours or more.
Sleep Quality. The Pittsburgh Sleep Quality Index [69] was used to derive a global score of
sleep quality across seven domains. Scores greater than 5 indicate poor sleep quality and elevat-
ed sleep disturbances [69]. We categorized scores as follows: 5 or less = normal sleep, greater
than 5 = poor sleep. Regular use of sleep medication was determined by self-report of using
medications 3 or more times per week reported either on the PSQI or during medical
interview.
Multisystem Biological Risk Index (Allostatic Load). A total of 22 biomarkers were mea-
sured and included in the allostatic load score, representative of 7 different physiological sys-
tems. This included the cardiovascular system (systolic blood pressure, pulse pressure, and
heart rate), lipid metabolic system (triglycerides, high density lipoprotein (HDL), low density
lipoprotein (LDL), body mass index, and waist-hip ratio), glucose metabolic system (fasting
blood glucose, glycosylated hemoglobin, and the homeostasis model of assessment of insulin
resistance (HOMA-IR)), immune system (inflammatory markers: C-reactive protein, Interleu-
kin(IL)-6, e-Selectin, intracellular adhesion molecule-1, and fibrinogen), sympathetic nervous
system (SNS; Urinary norepinephrine and epinephrine), parasympathetic nervous system
(PNS; heart rate variability: standard deviation of R-R intervals, low frequency (LF) and high
frequency (HF) spectral power), and hypothalamic-pituitary-adrenal system (urinary cortisol
and serum dehydroepiandrosterone sulfate (DHEA-S)). The measurement methods have been
reported in detail in prior publications [65,67,68]. Multisystem biological risk was computed
by calculating a 0–1 risk score within each system, which reflects the proportion of biomarkers
within that system for which the participant’s values fall in the highest-risk quartile. The seven
proportional scores were then summed, with final risk scores ranging from 0–7. This summa-
tion allows for equal weighting of each system in the multisystem biological risk computation
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regardless of the number of biomarkers assessed within a system. Cut points for individual bio-
markers can be found in a previous report [67]. In addition, use of medication prescribed to
lower specific biomarkers of risk was considered an indication of dysregulation within that sys-
tem (e.g. anti-hypertensive medication indicates increased risk in the cardiovascular system).
We scored individuals as being in the high risk quartile of that biomarker for which the medi-
cation is known to target. This included medications for lowering blood pressure, heart rate,
glucose, cholesterol, and triglycerides. We also performed sensitivity analyses using a risk score
that did not include medication in the computation. The individual system score was comput-
ed if participants had half or more of the biomarkers for that system. A total of 116 participants
had only one missing system scores (91 missing PNS scores; 25 missing one of the other system
scores). Data were missing at random for all the systems except parasympathetic. For the para-
sympathetic, missingness was more common in older adults and was due to instrumentation
problems that led to poor quality data signals. For 91 patients who were missing only the para-
sympathetic system score, we used single mean conditional imputation that replaces missing
values with predicted values from a regression equation generated with non-missing data [70].
This equation estimates missing risk scores using participants’ scores on the other six systems,
age, gender, and race/ethnicity as predictors. The others missing system scores values were im-
puted with the modal value, which was zero. Individuals had to have 6 of the 7 system scores to
have a risk score computed. Bivariate associations of subscale scores of the multisystem biologi-
cal risk index are reported in S1 Table.
Additional Variables. In addition to the basic demographic factors (age, gender, race), our
analyses adjust for indicators of socioeconomic status, including education obtained ( high
school, some college, vs. college) and income/poverty ratio, and BMI. Chronic condition
scores of 0–8 indicate the number of reported conditions that might influence sleep (including
lung condition, cardiovascular disease, history of stroke, history of cancer, joint or bone ail-
ments, gastrointestinal distress, thyroid diseases, and/or neurological disorder). Vitality was as-
sessed by a three item scale asking participants to rate using a likert scale from 1 to 5: their
energy levels compared to five years ago, and rate how much they feel full of life and active.
Scale score ranges from 3 to 15 with higher scores indicating higher vitality. Self-evaluated
physical health was assessed with a single question asking participants to rate their physical
health as either poor = 1, fair = 2, good = 3, very good = 4, excellent = 5. As clinical depression
is associated with an increase in disease risk [71], and may contribute to the sleep and disease
relationship [64], the Center for Epidemiologic Studies Depression (CESD) scale [72] scores of
16 or greater were used to identify probable clinical depression based on established cutoffs
with high clinical sensitivity and specificity [73,74].
Statistical Analyses
Statistical analyses were performed using IBM SPSS statistics (v.21). Initial analyses tested for
differences in means or percentage within category in demographics and chronic conditions
across the four sleep duration categories, which was performed using ANOVA followed by
pairwise comparisons or chi squared test. Linear associations of covariates with multisystem bi-
ological risk scores were determined with Pearson correlation. Tests for differences in multisys-
tem biological risk between sleep duration categories and sleep quality categories were
performed using a linear mixed effects model that included a random intercept at the family
level (MIDUS includes twins and siblings) to account for within family correlations between
siblings and twins in the study sample (sibling/twin pair (n = 107) ICC = .50 indicated a rela-
tively high within group similarity). Model 1 adjusts for age, gender, race (white vs. non-
white), education, income to poverty ratio, and BMI (to adjust for any residual variance
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accounted for by BMI), and tests for differences between: 1) sleep categories using normal du-
ration (6.5 to<8.5 hours per night) as the reference, and 2) sleep quality groups using normal
quality sleepers as the reference. In addition to adjusting for Model 1 covariates, Model 2 ad-
justs for comorbid chronic conditions and self-evaluated physical health. Secondary mixed lin-
ear effect models using case selection explore differences in long sleepers with or without poor
sleep quality and further adjusting for depression, and examine differences by sleep duration
category in the good sleep quality group.
Results
Descriptive statistics of the sample, along with statistics by sleep category, can be found in
Table 1. Differences between sleep categories in demographic factors were present, with a
greater percentage of Whites sleeping longer than non-Whites. Average BMI differed by sleep
category with short sleepers having the highest mean BMI. Poor sleep quality was more likely
to occur in non-Whites and women (p’s< .05). Poor sleepers compared to normal sleepers
had significantly lower average age, higher BMI, more chronic conditions, poorer self-rated
health, lower vitality, higher depressive symptoms, and lower income to poverty ratio (all
p’s< .05).
Correlation analyses showed that higher multisystem biological risk was significantly associ-
ated with older age (r = .44, p< .001), higher BMI (r = .34, p< .001), more chronic conditions
(r = .25, p< .001), poorer vitality (r = -.13, p< .001), a trend for higher depressive symptoms
scores (r = .06, p< .08), and poorer self-evaluated health (r = -.30, p< .001). Lower educational
attainment was associated with significantly higher multisystem biological risk (p< .001).
Table 1. Means (Standard Deviations) or percentages by sleep duration category.
Total Sample < 5 hrs. 5 to < 6.5 hrs. 6.5 to < 8.5 hrs.  8.5 P value
n = 1023 n = 42 n = 260 n = 635 n = 86
Age 54.5(11.8) 52.4(10.7) 52.7(11.5) 55.0(11.8) 56.7(12.2) 0.007a
Race <0.0001
% of White 77.6% 52.4% 74.2% 80% 86%
% of Non-White 22.4% 47.6% 25.8% 20% 14%
Gender 0.75
% Male 44% 42.9% 43.1% 45.2% 39.5%
% Female 56% 57.1% 56.9% 54.8% 60.5%
Body Mass Index (BMI) 29.7(6.6) 31.4(8.6) 30.5(7.2) 29.4(6.3) 28.7(5.4) 0.02 b
Income Poverty Ratio 5.2(4.2) 4.1(3.7) 5.1(4.1) 5.4(4.2) 5.0(4.2) 0.21
Education 0.20
 High School 27.4% 31% 30.8% 25.2% 31.4%
Some College 29.9% 35.7% 31.9% 28.8% 29.1%
 College Degree 42.7% 33.3% 37.3% 46% 39.5%
Chronic Conditions (0–8) 1.1(1.1) 1.4(1.2) 1.1(1.1) 1.1(1.1) 1.2(1.1) 0.25
Self-Rated Health (1–5, 1 = Poor) 3.7(.95) 3.4(1.1) 3.5(1.0) 3.8(.9) 3.5(1.0) <0.001c
CESD Depression (% 16 or greater) 13.7% 33.3% 20.4% 9.6% 14% <0.001
PSQI Global (% >5) 40.4% 100% 69.9% 27.7% 15.4% <0.001
a Difference at p < .05: 6.5 to <8.5 vs. 5 to <6.5,  8.5 vs. 5 to <6.5.
b Difference at p < .05: <5 to  8.5, 5 to <6.5 vs. 6.5 to < 8.5,  8.5 vs. 5 to <6.5
c Difference at p <.05: 6.5 to <8.5 vs. all other categories.
doi:10.1371/journal.pone.0118467.t001
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Sleep Duration and Multisystem Risk
As compared to normal sleepers, linear mixed effect analyses adjusting for age, gender, race,
education, income to poverty ratio, and BMI revealed that multisystem biological risk scores
were elevated in both short (B(SE) = .43(.15), p = .004) and long sleepers (B(SE) = .34(.11), p =
.001). Means by group are displayed in Fig. 1. Tests for the interaction of age with sleep dura-
tion and gender with sleep duration was not significant.
Next we ran a separate model testing for the effect of sleep duration on multisystem biologi-
cal risk after adjustment by health status (Model 2: chronic conditions and self-reported physi-
cal health; See Table 2). After adjusting for health status, the difference in multisystem
biological risk in both short sleepers and long sleepers compared to normal sleepers remained
Fig 1. Estimated mean and standard error of multisystem biological risk by sleep duration (1a) and PSQI global sleep score (1b).Mean and
standard error estimates derived frommodel after adjustments by age, gender, race, BMI, education, income poverty ratio, chronic conditions, and self-
evaluated physical health. Multisystem Biological Risk score ranged from 0–7.
doi:10.1371/journal.pone.0118467.g001
Table 2. Mixed linear effect model coefficients (B) for multisystem biological risk by sleep quality and duration.
PSQI Normal vs. Poor
Quality Sleep
Short vs. Normal Sleep
Duration
Long vs. Normal Sleep
Duration
B(SE) p value B(SE) p value B(SE) p value
Unadjusted .17(.07) .02 .47(.18) .009 .38(.13) .003
Model 1 .15(.06) .01 .43(.15) .004 .34(.11) .001
Model 2 Health status .09(.06) .16 .38(.15) .009 .28(.11) .008
Model 1: age, gender, race, BMI, education, income poverty ratio
Model 2: age, gender, race, BMI, education, income poverty ratio, chronic conditions, self-evaluated health
doi:10.1371/journal.pone.0118467.t002
Sleep and Disease Risk
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significant, p< .01. We ran sensitively analyses, excluding 31 participants with HIV and neuro-
logical conditions and found no difference in the findings.
Sleep Quality and Multisystem Biological Risk
As compared to those with normal sleep quality, linear mixed effect analyses adjusting for age,
gender, race, education, income to poverty ratio, and BMI revealed that participants with poor
sleep quality had elevated multisystem biological risk scores, B(SE) = .15(.06), p = .01. Results
were no longer significant after adjustment for health status, B(SE) = .09 (.06), p = .16.
Poor Quality Sleep and Sleep Duration
All short sleepers reported poor sleep quality, and there were no cases of short sleep and good
quality sleep. Due to concerns that short sleep duration might contribute to higher PSQI scores,
we also computed the PSQI without the sleep duration item. Among the 42 subjects in the
group who were short sleepers with poor sleep quality, only 4 subjects were re-classified when
the sleep duration item was no longer considered in determining poor sleep quality. Hence, in
the short sleepers who have high PSQI scores, poor sleep quality is not driven by the single
item related to sleep duration.
To examine whether the elevated multisystem biological risk differed in long sleepers who
reported either normal or poor sleep quality, we stratified the long sleep duration group (n =
86) on the basis of sleep quality scores. As compared to long sleepers with normal sleep quality,
long sleepers reporting poor sleep quality had significantly elevated multisystem biological risk,
B(SE) = .93(.3), p = .002 after adjustment for sociodemographic factors, and remained signifi-
cant after adjustment for health status (B(SE) = .79(.3), p = .009). Fig. 2 displays the adjusted
means within sleep quality group by sleep duration categories. Secondary mixed linear effect
analyses selecting only those cases reporting normal quality sleep demonstrated that long sleep
duration compared to normal sleep duration was not associated with elevated multisystem risk
among individuals reporting normal quality sleep (B(SE) = .17(.12), p = .14).
Depression
As a secondary inquiry, we examined whether depressive symptoms might explain the elevated
multisystem risk observed in short sleepers and among long sleepers with poor sleep quality.
As Table 1 shows, 33% of short sleepers were in the high depressive symptoms group. Howev-
er, further adjustment by depressive symptoms status did not alter the findings showing elevat-
ed multisystem risk in short sleepers (B(SE) = .42(.15), p = .005). Similarly, the percentage of
subjects with high depressive symptoms in the long sleepers varied by sleep quality status, with
37.6% of poor sleep quality subjects reporting high depressive symptoms, while 8.6% of normal
quality sleepers fell into the high depressive symptoms category (χ2 = 9.1, p< .005). Difference
between poor sleep quality and normal sleep quality in multisystem biological risk among long
sleepers remained significant after adjustment by depressive symptoms (B(SE) = .71(.31), p =
.02).
Analyses examining associations of sleep duration and quality with each individual system
risk score included in the multisystem biological risk index are available in the supplemental
material, S2 Table.
Discussion
The present set of analyses report significantly elevated multisystem biological risk scores in
short sleepers, those reporting sleeping less than 5 hours a night, all of which report poor sleep
Sleep and Disease Risk
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quality. These finding are consistent with reports of elevated mortality risk is short sleepers
and point to a possible mechanism through which inadequate sleep influences disease risk. The
findings linking short sleep with elevated multisystem biological risk was retained after further
adjustment by health status and depression suggesting that these factors do not account for the
differences observed.
Our findings showing that inadequate sleep is associated with increased multisystem biolog-
ical risk strengthens the existing research documenting similar associations of short sleep dura-
tion with a greater likelihood of exhibiting elevated biological risk across several individual
regulatory systems (e.g., metabolic syndrome, hypertension, glucose regulation, immune, en-
docrine, autonomic). Likewise, the results are consistent with previous findings linking short
sleep and sleep disturbances with allostatic load using measures that capture metabolic, cardio-
vascular, and immune systems [62,63]. However, the current study is the first to date to exam-
ine the relationship of sleep with multisystem biological risk, including sympathovagal and
neuroendocrine parameters, and is comprised of 22 biomarkers specifically designed to capture
allostatic load. These findings have significant clinical value given that over half of these bio-
markers are commonly used individually to designate a unique disease risk (i.e., Hemoglobin
A1c and diabetes) and are used together to predict morbidity and mortality outcomes [17,59–
61].
Fig 2. Estimated mean and standard error of multisystem biological risk by sleep duration and quality.Mean and standard error estimates derived
frommodel after adjustments by age, gender, race, BMI, education, income poverty ratio, chronic conditions, and self-evaluated physical health. Multisystem
Biological Risk score ranged from 0–7.
doi:10.1371/journal.pone.0118467.g002
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Multisystem biological risk scores of long sleepers were also elevated compared to normal
sleepers, but this difference was only in the long sleepers with poor sleep quality, an effect that
remained after adjustment for depression. It was hypothesized that one possibility for elevated
multisystem biological risk (and increased risk of mortality) in long sleepers is that individuals
who sleep for longer periods than normal often have poorer sleep quality. Our result suggest
that poor sleep quality in long sleepers contributes to elevated multisystem biological risk. This
finding supports the hypothesis that too much sleep is associated with elevated risk because it
may in fact serve as a proxy indicator of sleep fragmentation where individuals do not actually
obtain the amount of sleep needed, which in turn increases the drive to sleep longer [8]. Under
this hypothesis, sleep fragmentation could contribute to increased demands of the regulatory
systems to maintain allostasis [14]. Since we were unable to directly test sleep apnea in the pres-
ent analyses, it remains possible that our sample of long sleepers with poor sleep quality may
include individuals with sleep apnea, and future research should consider this possibility.
Of particular note to medical professionals, these findings highlight the importance of sleep
duration and the role of sleep quality as potential risk factors contributing to shifts in biological
risk indicators. Similar to physician queries of other behavioral risk factors like smoking, low
physical activity, and excess alcohol consumption, queries about sleep amounts and quality
may be relevant [75].
Mechanisms
A remaining question is why short sleep and poor sleep quality in long sleepers might impact
these regulatory systems and how this might influence risk for disease. Sleep serves an impor-
tant evolutionary function; it give the body time to rest and repair damage [75,76]. In the case
of short sleep and sleep fragmentation, inadequate and disturbed sleep places demands on mul-
tiple regulatory systems throughout the body by reducing the available time for restoration and
increasing the demand on physiological resources necessary to maintain stability (i.e., allosta-
sis) [14]. Over time the accumulation of demands without appropriate restoration causes wear
and tear, evidenced by allostatic load [15,16]. Thus prolonged periods of inadequate sleep likely
contribute to gradual shifts in regulatory set points such as resting blood pressure, cholesterol,
blood sugar, and inflammatory activity, which are themselves known to be involved in the
pathophysiology of disease [55–57,77–79].
Limitations and Strengths
Our findings are cross-sectional and thus do not show causation. Future work should focus on
applying longitudinal and experimental designs to assess causality. Similarly, treatment trials
to improve sleep in short sleepers and long sleepers with poor sleep quality are needed to exam-
ine whether multisystem biological risk improves along with remission of sleep problems. As
previously stated, using self-reported sleep is limited and more objective measures of sleep con-
tinuity, along with a careful assessment for sleep apnea, would greatly improve our understand-
ing of the links between short and long sleep with multisystem biological risk. There are
numerous strengths to the current study including a large heterogeneous sample of adults in
the US increasing the generalizability of the findings, and a comprehensive 22 biomarker mea-
sure of multisystem biological risk with established predictive validity for morbidity and mor-
tality outcomes. In addition, the MIDUS study includes a detailed assessment of health,
including an extensive assessment of self-reported chronic conditions, which allows us to con-
trol for the possible confound of health when examining relationships of sleep with biological
risk. Likewise, the inclusion of a well validated and reliable measure of depressive symptoms
(the CESD) [72,73] adds to the strength of the current analyses revealing that further statistical
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adjustments for depression does not account for the differences in multisystem biological risk
among short sleepers and long sleepers with poor sleep quality.
Conclusions
In sum, we report in a large community based sample of adults living in the Unites States of
America that similar to findings linking sleep duration with mortality risk, short sleepers and
long sleepers with poor sleep quality had elevated biomarkers of risk indicative of multisystem
dysregulation. This finding was independent of sociodemographics, chronic health conditions,
self-evaluated health, and depression. The association of long sleepers with elevated multisys-
tem biological risk was only present in those reporting poor sleep quality, suggesting that self-
reported long sleep may be related to disease partially because it captures poor sleepers. Poor
and inadequate sleep may contribute to dysregulation in physiological set points across numer-
ous regulatory systems, represented as allostatic load. These findings suggest that acquiring ad-
equate amounts of good quality sleep (at least greater than 5 hours) is associated with less
multisystem biological risk, and may therefore also be a means to lower risk for morbidity and
mortality. Individuals who report global poor sleep quality (>5 on PSQI), either with long
sleep or short sleep, are also experiencing some insomnia symptoms. Meta-analytic evidence
suggests that both insomnia symptoms and global sleep quality are improved with behavioral
interventions (e.g., cognitive behavioral therapy for insomnia, CBT-I) [61], suggesting that
such treatments may also be useful in improving sleep quality even among those who do not
meet full criterion for insomnia disorder. Future research should examine the treatment effica-
cy of CBT-I and possibly other behavioral interventions for subsyndromal insomnia as indicat-
ed by high global PSQI scores with short or long sleep duration. In the case of long sleep,
current interventions are underway to target sleep restriction in long sleepers as a means to im-
prove health, which may act by resetting diurnal rhythms [80]. The present findings point to
the importance of evaluating sleep amounts and quality during assessment of lifestyle factors
associated with cardiovascular and other disease risk.
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